Fibrilación auricular: fisiopatología, factores de riesgo y rol de la anticoagulación oral
Atrial fibrillation: pathophysiology, risk factors and the role of the oral anticoagulatio
Barra lateral del artículo
PDF
FLIP
Contenido principal del artículo
Resumen
Introducción: la fibrilación auricular es la arritmia cardíaca más frecuente a nivel mundial, considerándose un problema importante de salud pública dada su elevada morbimortalidad y alta carga económica asociada al ataque cerebrovascular como su principal complicación tromboembólica.Objetivo: hacer una revisión narrativa de los aspectos fisiopatológicos, factores de riesgo y de la terapia anticoagulante oral en pacientes con fibrilación auricular. Métodos: utilizando las palabras claves se realizó una revisión no sistemática de la literatura disponible, tanto en inglés como en español, en las bases de datos PubMed, Science Direct, Embase, EBSCO y MEDLINE. Se seleccionaron 68 publicaciones entre ellas guías de práctica clínica, metaanálisis, revisiones sistemáticas, ensayos clínicos y artículos originales que daban respuesta a nuestro objetivo con la mejor evidencia posible. Resultados: en el inicio y mantenimiento de la fibrilación auricular participan factores de riesgos modificables y no modificables, los cuales inciden en su fisiopatología generando tanto trastornos de la formación del impulso como trastornos de la conducción. En las últimas décadas los anticoagulantes orales directos han comprobado igual o mayor beneficio que la warfarina, con menores tasas de efectos adversos en pacientes con fibrilación auricular no valvular. Incluso, algunos estudios sugieren la extensión de uso en fibrilación auricular valvular. Sin embargo, la warfarina sigue siendo el fármaco de elección con mayor evidencia en esta última. Conclusión: la fibrilación auricular es una arritmia cuya incidencia va en aumento dado la mayor prevalencia de factores de riesgo en la población. La anticoagulación es un pilar en la prevención del ataque cerebrovascular. Debe instaurarse con un enfoque individualizado teniendo en cuenta los efectos adversos y beneficios de cada fármaco, el perfil del paciente, el riesgo de ataque cerebrovascular y el riesgo de hemorragia mediante el uso de escalas.
Palabras clave:
Descargas
Detalles del artículo
Referencias (VER)
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;1–126. doi: 10.1093/eurheartj/ehaa612
Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;319(21):1374–8. doi: 10.1056/NEJM198204293061703
Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: A historical perspective. Lancet. 2014;383(9921):999–1008. doi: 10.1016/S0140-6736(13)61752-3
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation. 2014; 129(8):837–47. doi: 10.1161/circulationaha.113.005119
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Vol. 139, Circulation. 2019. 56–528 p. doi: 10.1161/CIR.0000000000000659
Heeringa J, Van Der Kuip DAM, Hofman A, Kors JA, Van Herpen G, Stricker BHC, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J. 2006;27(8):949–53. doi: 10.1093/eurheartj/ehi825
Mina K. C, Refaat Marwan. Fibrilación auricular. J Am Coll Cardiol. 2020;75(14). doi: 10.1016/j.jacc.2020.02.025
Merino JL. Mecanismos electrofisiológicos y diagnóstico de la fibrilación auricular. Rev Esp Cardiol. 2016;16:12–9. doi: 10.1016/S1131-3587(16)30009-7
Romero M, Chávez D. Carga de enfermedad atribuible a fibrilación auricular en Colombia (2000-2009). Rev Colomb Cardiol. 2014;21(6):374–81. doi: 10.1016/j.rccar.2014.08.006
Rosselli D, Rodríguez AJ, García ÁA, Rueda JD. Prevalencia de fibrilación auricular en un hospital universitario colombiano. Rev Colomb Cardiol. 2013;20(6):383–5. doi: 10.1016/S0120-5633(13)70089-5
Gómez-Outes A, Lagunar-Ruíz J, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Causes of Death in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2016;68(23):2508–21. doi: 10.1016/j.jacc.2016.09.944
Ruddox V, Sandven I, Munkhaugen J, Skattebu J, Edvardsen T, Otterstad JE. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24(14):1555–66. doi: 10.1177/2047487317715769
Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1859–922. doi: 10.1016/S0140-6736(18)32335-3
Sudharsanan N, Deshmukh M, Kalkonde Y. Direct estimates of disability-adjusted life years lost due to stroke: A cross-sectional observational study in a demographic surveillance site in rural Gadchiroli, India. BMJ Open. 2019;9(11):1–8. doi: 10.1136/bmjopen-2018-028695
Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009;8(4):355–69. doi: 10.1016/S1474-4422(09)70025-0
Epstein AE. Relationships between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109(12):1509–13. doi: 10.1161/01.CIR.0000121736.16643.11
Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998;98(10):946–52. doi: 10.1161/01.CIR.98.10.946
Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: The framingham heart study. Circulation. 2004;110(9):1042–6. doi: 10.1161/01.CIR.0000140263.20897.42
Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2(2). doi: 10.1161/JAHA.112.000102
Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation: The Framingham Heart Study. Circulation. 1994;89(2):724–30. doi: 10.1161/01.CIR.89.2.724
Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: Epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol. 2016;13(6):321–32. doi: 10.1038/nrcardio.2016.45
Magnani JW, Moser CB, Murabito JM, Sullivan LM, Wang N, Ellinor PT, et al. Association of sex hormones, aging, and atrial fibrillation in men the framingham heart study. Circ Arrhythmia Electrophysiol. 2014;7(2):307–12. doi: 10.1161/CIRCEP.113.001322
Alkhouli M, Friedman PA. Ischemic Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;74(24):3050–65. doi: 10.1016/j.jacc.2019.10.040
Benjamin E, D´Agostino R, Belanger A. Left Atrial Size and the Risk of Stroke and Death. Chest. 1995;92(4):390–2. doi: 10.1161/01.cir.92.4.835
Ogata T, Matsuo R, Kiyuna F, Hata J, Ago T, Tsuboi Y, et al. Left Atrial Size and Long-Term Risk of Recurrent Stroke After Acute Ischemic Stroke in Patients With Nonvalvular Atrial Fibrillation. doi: 10.1161/JAHA.117
Leong DP, Joyce E, Debonnaire P, Katsanos S, Holman ER, Schalij MJ, et al. Left Atrial Dysfunction in the Pathogenesis of Cryptogenic Stroke: Novel Insights from Speckle-Tracking Echocardiography. J Am Soc Echocardiogr. 2017;30(1):71-79. e1. doi: 10.1016/j.echo.2016.09.013
Daccarett M, Badger TJ, Akoum N, Burgon NS, Mahnkopf C, Vergara G, et al. Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol. 2011;57(7):831–8. doi: 10.1016/j.jacc.2010.09.049
Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61(2):755–9. doi: 10.1016/0003-4975(95)00887-X
Lupercio F, Carlos Ruiz J, Briceno DF, Romero J, Villablanca PA, Berardi C, et al. Left atrial appendage morphology assessment for risk stratification of embolic stroke in patients with atrial fibrillation: A meta-analysis. Hear Rhythm. 2016;13(7):1402–9. doi: 10.1016/j.hrthm.2016.03.042
Di Biase L, Santangeli P, Anselmino M, Mohanty P, Salvetti I, Gili S, et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol. 2012;60(6):531–8. doi: 10.1016/j.jacc.2012.04.032
Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T, et al. Obstructive Sleep Apnea, Obesity, and the Risk of Incident Atrial Fibrillation. J Am Coll Cardiol. 2007;49(5):565–71. doi: 10.1016/j.jacc.2006.08.060
Para O, Caruso L, Corbo L, Bacci F, Pasqui N, Pieralli F, et al. Risk factors and outcomes of new-onset atrial fibrillation in patients hospitalized in an internal medicine ward: a case–control study. Intern Emerg Med. 2020;15(2):251–6. doi: 10.1007/s11739-019-02151-y
Gaztañaga L, Marchlinski FE, Betensky BP. Mecanismos de las arritmias cardiacas. Rev Esp Cardiol. 2012;65(2):174–85. doi: 10.1016/j.recesp.2011.09.018
Zemlin CW, Mitrea BG, Pertsov AM. Spontaneous onset of atrial fibrillation. Phys D Nonlinear Phenom. 2009;238(11–12):969–75. doi: 10.1016/j.physd.2008.12.004
Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: A translational appraisal. Physiol Rev. 2011;91(1):265–325. doi: 10.1152/physrev.00031.2009
Allessie MA, Konings K, Kirchhof CJHJ, Wijffels M. Electrophysiologic mechanisms of perpetuation of atrial fibrillation. Am J Cardiol. 1996;77(3):10A-23A. doi: 10.1016/S0002-9149(97)89114-X
Thijssen VLJL, Ausma J, Liu GS, Allessie MA, Van Eys GJJM, Borgers M. Structural changes of atrial myocardium during chronic atrial fibrillation. Cardiovasc Pathol. 2000;9(1):17–28. doi: 10.1016/S1054-8807(99)00038-1
Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial Fibrillation Begets Atrial Fibrillation. Circulation. 1995 Oct 1;92(7):1954–68. doi: 10.1161/01.CIR.92.7.1954
Sheng X, Scherlag BJ, Yu L, Li S, Ali R, Zhang Y, et al. Prevention and reversal of atrial fibrillation inducibility and autonomic remodeling by low-level vagosympathetic nerve stimulation. J Am Coll Cardiol. 2011 Feb 1;57(5):563–71. doi: 10.1016/j.jacc.2010.09.034
Heidenreich PA, Solis P, Estes NAM, Fonarow GC, Jurgens CY, Marine JE, et al. 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2016;68(5):525–68. doi: 10.1016/j.jacc.2016.03.521
Lip GYH. Implications of the CHA2DS2-VASc and HAS-BLED scores for thromboprophylaxis in atrial fibrillation. Am J Med. 2011;124(2):111–4. doi: 10.1016/j.amjmed.2010.05.007
Lip GYH, Tse HF, Lane DA. Atrial fibrillation. Lancet. 2012;379(9816):648–61. doi: 10.1016/S0140-6736(11)61514-6
Kernich CA. Ischemic stroke. Neurologist. 2007;13(4):235–6. doi: 10.1097/NRL.0b013e3180a032ca
Kimura K, Minemaisu K, Yamaguchi T. Atrial fibrillation as a predictive factor for severe stroke and early death in 15 831 patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry. 2005;76(5):679–83. doi: 10.1136/jnnp.2004.048827
Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby J V., et al. Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. N Engl J Med. 2003 Sep 11;349(11):1019–26. doi: 10.1056/nejmoa022913
Whalen K. Agentes anticoagulantes y antiplaquetarios. In: Vogel Anderson K, Smith Kaylie, editors. Lippincott Illustrated Reviews: Farmacología. 7th ed. Wolters Kluwer; 2019. p. 498–530.
Olesen JB, Lip GYH, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a “real world” nationwide cohort study. Thromb Haemost. 2011;106(4):739–49. doi: 10.1160/TH11-05-0364
Friberg L, Rosenqvist M, Lip GYH. Net clinical benefit of warfarin in patients with atrial fibrillation: A report from the swedish atrial fibrillation cohort study. Circulation. 2012;125(19):2298–307. doi: 10.1161/Circulationaha.111.055079
Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc Score (Beyond Sex) receive oral anticoagulation? J Am Coll Cardiol. 2015;65(7):635–42. doi: 10.1016/j.jacc.2014.11.046
Escribá A, Gil R. Trastornos hemorrágicos en el recién nacido. An pediatría. 2010;8(2):64–72. doi: 10.1016/S1696-2818(10)70012-3
Aursulesei V, Costache II. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol. 2019 Aug 28;42(8):774–82. doi: 10.1002/clc.23196
Hart R, Pearce L, Aguilar M. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67. doi: 10.7326/0003-4819-146-12-200706190-00007
Hughes M, Lip GYH. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: A systematic review. QJM. 2007;100(10):599–607. doi: 10.1093/qjmed/hcm076
Yao X, Abraham NS, Caleb Alexander G, Crown W, Montori VM, Sangaralingham LR, et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016 Feb 1;5(2):1–12. doi: 10.1161/JAHA.115.003074
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation * A complete listing of the steering com-mittee members and trial investigators in the Rivaroxaban Once Daily Oral Di-rect Factor Xa Inhibition Compared with Vitamin K Antagonism for Preven-tion of Stroke and Embolism Trial in Atrial Fibrillation. N Engl J Med. 2011; 365:883–91. doi: 10.1056/NEJMoa1009638
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139–51. doi: 10.1056/nejmoa0905561
Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011 Sep 15;365(11):981–92. doi: 10.1056/nejmoa1107039
Guimarães HP, Lopes RD, de Barros e Silva PGM, Liporace IL, Sampaio RO, Tarasoutchi F, et al. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. N Engl J Med. 2020;383(22):2117–26. doi: 10.1056/nejmoa2029603
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. doi: 10.1016/S0140-6736(13)62343-0
Hogg K, I. Weitz J. Coagulación sanguínea y anticoagulantes, fibrinolíticos y antiagregantes plaquetarios. In: Las bases farmacologicas de la terapéutica. 13th ed. 2019. p. 585–603.
Gottlieb M, Khishfe B. Idarucizumab for the Reversal of Dabigatran. Ann Emerg Med. 2017;69(5):554–8. doi: 10.1016/j.annemergmed.2016.11.025
Ordovás Baines JP, Climent Grana E, Jover Botella A, Valero García I. Farmacocinética y farmacodinamia de los nuevos anticoagulantes orales. Farm Hosp. 2009;33(3):125–33. doi: 10.1016/s1130-6343(09)71154-7
Ng KH, Shestakovska O, Connolly SJ, Eikelboom JW, Avezum A, Diaz R, et al. Efficacy and safety of apixaban compared with aspirin in the elderly: A subgroup analysis from the AVERROES trial. Age Ageing. 2016;45(1):77–83. doi: 10.1093/ageing/afv156
Streiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, Lopes R, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016;41(1):32–67. doi: 10.1007/s11239-015-1317-0
Belmar Vega L, de Francisco ALM, Bada da Silva J, Galván Espinoza L, Fernández Fresnedo G. Nuevos anticoagulantes orales en pacientes con enfermedad renal crónica. Nefrología. 2017;37(3):244–52. doi: 10.1016/j.nefro.2016.08.006
Olaya A, Villamizar A. Memocardio No.14 Anticoagulantes orales en pacientes con fibrilación auricular no valvular con falla renal crónica avanzada o en hemodiálisis – SCC. Sociedad Colombiana de Cardiologia [Internet]. 2020 [cited 2021 Jan 3]; Available from: https://scc.org.co/memocardio-no-14-anticoagulantes-orales-en-pacientes-con-fibrilacion-auricular-no-valvular-con-falla-renal-cronica-avanzada-o-en-hemodialisis/
Randhawa MS, Vishwanath R, Rai MP, Wang L, Randhawa AK, Abela G, et al. Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease: A Systematic Review and Meta-analysis. JAMA Netw open. 2020;3(4):e202175. doi: 10.1001/jamanetworkopen.2020.2175
Feldberg J, Patel P, Farrell A, Sivarajahkumar S, Cameron K, Ma J, et al. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Nephrol Dial Transplant. 2019;34(2):265–77. doi: 10.1093/ndt/gfy031
